亚太放射性药物的市场分析By Product (Diagnostics: SPECT, PET; Therapeutics: Alpha Emitters, Beta Emitters, Brachytherapy), By Type (Catheter, Doppler OCT, Handheld, Tabletop), By Application (Diagnostics: Cardiology, Neurology, Oncology, Thyroid, Lymphoma; Therapeutics: Thyroid, Bone Metastasis, Lymphoma, Endocrine Tumor) And Segment Forecasts to 2024

Market Segmentation

• APAC Radiopharmaceuticals Market by Product (USD Million), 2013 - 2024
  • Diagnostics
    • SPECT
      • TC-99m
      • TL-201
      • GA-67
      • I-123
      • Others
    • PET
      • F-18
      • RB-82
      • Others
  • Therapeutics
    • Alpha Emitters
      • RA-223
    • Beta Emitters
      • I-131
      • Y-90
      • SM-153
      • Re-186
      • Lu-117
      • Others
  • Brachytherapy
    • Cesium-131
    • Iodine-125
    • Palladium-103
    • Iridium-192
    • Others
• APAC Radiopharmaceuticals Market by Application (USD Million), 2013 - 2024
  • Diagnostics
  • Cardiology
  • Neurology
  • Oncology
  • Thyroid
  • Lymphoma
  • Therapeutics
  • Thyroid
  • Bone Metastasis
  • Lymphoma
  • Endocrine Tumor
• APAC Radiopharmaceuticals Market by Region (USD Million), 2013 - 2024
  • South East Asia
    • Indonesia
    • Thailand
    • Laos
    • Myanmar
    • Philippines
    • Malaysia
    • Vietnam
    • Cambodia
  • Rest of Asia Pacific
    • Japan
    • China
    • India

Report Content

Qualitative Analysis

• Industry overview
• Industry trends
• Market drivers and restraints
• 乐鱼体育手机网站入口
• Growth prospects
• Porter’s analysis
• PESTEL analysis
• Key market opportunities prioritized
• Competitive landscape
  • Company overview
  • Financial performance
  • Product benchmarking
  • Latest strategic developments

Quantitative Analysis

• Market size, estimates, and forecast from 2013 to 2024
• Revenue estimates for technology up to 2024
• Revenue estimates for type up to 2024
• Revenue estimates for application up to 2024
• Regional market size and forecast for product up to 2024